Objective: To investigate whether lncRNA H19 can regulate NF1 expression through competitive binding to microRNA-107, thereby participating in the occurrence and development of non-small cell lung cancer (NSCLC).

Patients And Methods: Expression levels of H19 and NF1 in NSCLC tissues, paracancerous tissues and NSCLC cell lines were detected by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR). The binding condition of microRNA-107, H19 and NF1 was detected by dual-luciferase reporter gene assay. Corresponding lentiviruses of H19 were constructed. The regulatory effects of H19 on proliferative and migratory abilities of A549 cells were detected by cell counting kit-8 (CCK-8) and transwell assay, respectively. Rescue experiments were conducted to explore the regulatory interaction between H19 and microRNA-107 in A549 cells.

Results: H19 and NF1 were highly expressed in NSCLC tissues and NSCLC cell lines (A549 and HCC823) than those of controls. Overexpressed H19 increased proliferative and migratory abilities of A549 cells. Dual-luciferase reporter gene assay demonstrated that H19 regulates NF1 expression through competitive binding to microRNA-107, thereafter participating in NSCLC development.

Conclusions: H19 is highly expressed in NSCLC, which promotes NSCLC development by regulating NF1 via competitive binding to microRNA-107.

Download full-text PDF

Source
http://dx.doi.org/10.26355/eurrev_201809_15925DOI Listing

Publication Analysis

Top Keywords

competitive binding
12
binding microrna-107
12
h19 nf1
12
h19
10
lncrna h19
8
non-small cell
8
cell lung
8
lung cancer
8
development regulating
8
nf1 expression
8

Similar Publications

A High-Throughput Screening Pipeline to Identify Methyltransferase and Exonuclease Inhibitors of SARS-CoV-2 NSP14.

Biochemistry

January 2025

National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850, United States.

SARS-CoV-2 infections led to a worldwide pandemic in 2020. As of 2024, therapeutics against SARS-CoV-2 have continued to be desirable. NSP14 is a dual-function methyltransferase (MTase) and exonuclease (ExoN) with key roles in SARS-CoV-2 genome propagation and host immune system evasion.

View Article and Find Full Text PDF

The effect of incorporating 4-hydroxy-2,5-dimethyl-3(2H)-furanone (furaneol) during soy protein isolate (SPI) preparation on off-flavor compounds was investigated. Sensory evaluation revealed that furaneol addition effectively reduced undesirable attributes such as grain husk, grassy, raw bean, tofu and oil oxidation, with the most significant decrease at 2 mg/L. Flavor analysis confirmed a significant reduction in both the variety and amount of off-flavors.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

Background: Plasma phospho-tau217 (p-tau217) is a promising blood-based biomarkers for Alzheimer's disease (AD). However, the accessibility of pTau217 tests for both research and clinical applications has been constrained. Previous studies focused on highly-phenotyped cohorts that differ substantially from the wider population.

View Article and Find Full Text PDF
Article Synopsis
  • Solid-state polymer electrolytes (SPEs) are gaining attention for sodium metal batteries (SMBs) due to their flexibility and lower interfacial resistance, but they struggle with sodium ion conductivity and unstable interfaces.
  • A novel composite electrolyte called PPNM is created by integrating a 3D copper metal organic framework (Cu-MOF) with polyacrylonitrile (PAN) fibers and polyethylene oxide (PEO), enhancing ionic conductivity and sodium ion movement.
  • The improved stability and performance of the PPNM electrolyte lead to strong cycling results for Na3V2(PO4)3@C/PPNM/Na full cells, making it a promising strategy for advancing solid-state SMB technology.
View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

AC Immune SA, Lausanne, Switzerland.

Background: The key advantage of active immunization is the induction of sustained, polyclonal antibody responses that are readily boosted by occasional immunizations. Recent clinical trial outcomes for monoclonal antibodies lecanemab and donanemab, establish the relevance of targeting pathological Abeta for clearing amyloid plaques in Alzheimer's disease. ACI-24.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!